Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune mediated inflammatory disorders including Crohn's disease and ulcerative colitis. Globally over 600000 patients have been treated with infliximab to date. This global experience led to a better definition of the overall safety and efficacy profile of this medication. The goal of the present recommendations is to provide practical information to physicians involved in the care of patients with inflammatory bowel disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
[infliximab--practical guidelines
4
guidelines treatment
4
treatment crohn's
4
crohn's disease]
4
disease] infliximab
4
infliximab monoclonal
4
monoclonal chimeric
4
chimeric antibody
4
antibody high
4
high affinity
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!